84745-95-9

Basic information

• Product Name: Eriocalyxin B
• Synonyms: Eriocalyxin B
• CAS NO: 84745-95-9
• Molecular Formula: C20H24O5
• Molecular Weight: 344.4016
• Product Categories: Diterpenoids
• Mol File: 84745-95-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 551.1 °C at 760 mmHg
• Flash Point: 198.9 °C
• Appearance: /
• Density: 1.37 g/cm³
• PKA: 11.05±0.60(Predicted)
• CAS DataBase Reference: Eriocalyxin B(CAS DataBase Reference)
• NIST Chemistry Reference: Eriocalyxin B(84745-95-9)
• EPA Substance Registry System: Eriocalyxin B(84745-95-9)

Safety Data

• Hazardous Substances Data: 84745-95-9(Hazardous Substances Data)

Usage

General Description

Eriocalyxin B is a natural chemical compound derived from plants in the genus Isodon. It has been found to possess various biological activities, including anti-inflammatory, anti-cancer, and anti-malarial properties. Eriocalyxin B has been of particular interest in cancer research due to its ability to induce apoptosis (programmed cell death) in cancer cells, as well as its potential to inhibit metastasis and angiogenesis. The compound has also shown promise in alleviating symptoms of inflammatory conditions, such as arthritis, and has exhibited anti-malarial activity by targeting the parasite responsible for the disease. These properties make eriocalyxin B a potential candidate for the development of new therapeutic agents for cancer, inflammatory diseases, and malaria.

Relevant articles and documents

Scalable synthesis enabling multilevel bio-evaluations of natural products for discovery of lead compounds

Challenges in the development of anti-cancer chemotherapeutics continue to exist, particularly with respect to adverse effects and development of resistance, underlining the need for novel drugs with good safety profiles. Natural products have proven to be a fertile ground for exploitation, and development of anti-cancer drugs from structurally complex natural products holds promise. Unfortunately, this approach is often hindered by low isolation yields and limited information from preliminary cell-based assays. Here we report a concise and scalable synthesis of a series of low-Abundance Isodon diterpenoids (a large class of natural products with over 1000 members isolated from the herbs of genus Isodon, which are well-known folk medicines for the treatment of inflammation and cancer), including eriocalyxin B, neolaxiflorin L and xerophilusin I. These scalable syntheses enable multilevel bio-evaluation of the natural products, in which we identify neolaxiflorin L as a promising anti-cancer drug candidate.